A Comparison of the Appraisals by the English National Institute for Health and Care Excellence (NICE) for Two Therapies for Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL): Idelalisib+Rituximab (IR) and Ibrutinib
Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.407
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2017
Authors
Publisher
Elsevier BV